Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-12-06
2011-10-25
Navarro, Albert (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C702S019000
Reexamination Certificate
active
08043825
ABSTRACT:
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.
REFERENCES:
patent: 4705751 (1987-11-01), Mosher
patent: 5281522 (1994-01-01), Senyei et al.
patent: 5719060 (1998-02-01), Hutchens et al.
patent: 5786156 (1998-07-01), Taddei-Peters et al.
patent: 6030835 (2000-02-01), Musser et al.
patent: 6107045 (2000-08-01), Koren et al.
patent: 6156546 (2000-12-01), Konkel et al.
patent: 6225047 (2001-05-01), Hutchens et al.
patent: 6675104 (2004-01-01), Paulse et al.
patent: 7094549 (2006-08-01), Jackowski et al.
patent: 7605003 (2009-10-01), Chan et al.
patent: 2003/0054367 (2003-03-01), Rich et al.
patent: 2003/0078192 (2003-04-01), Winter et al.
patent: 2003/0108960 (2003-06-01), Zrein
patent: 2004/0096917 (2004-05-01), Ivey et al.
patent: 2005/0048519 (2005-03-01), Chien et al.
patent: 2005/0187159 (2005-08-01), Bridon et al.
patent: 2006/0253259 (2006-11-01), Fernandez
patent: 2007/0031832 (2007-02-01), Watt et al.
patent: 2009/0042229 (2009-02-01), Folkman et al.
patent: WO 99/41610 (1999-08-01), None
patent: 03/046569 (2003-06-01), None
Ouaissi, All et al, European Journal of Cell Biology, v. 59, 1992, p. 68-79.
Lohr et al, Blood, vol. 76(10) Nov. 15, 1990, pp. 2117-2224, The amino terminal 29- and 72-Kd fragments of Fibronectin Mediate Selective Monocyte recruitment.
Quade, Bradley J. et al, The Journal of Biological Chemistry, vol. 263(36), Dec. 25, 1988, pp. 19602-19609, Fibronectin's amino terminal matrix assembly site is located within the 29 kDa Amino-terminal domain containing Five Type I repeats.
Andrade, Sonia et al, Am. J. Trop. Med. Hyg., vo. 40(3), pp. 252-260, 1989Sequential changes of the connective matrix components of the myocardium (Fibronectin and Laminin) and evolution of cardiac fibrosis in mice infected withTrypanosoma cruzi.
Garcia-Pardo, Angeles et al, The Journal of Biological Chemistry, vol. 260(18) Aug. 25, 1985, pp. 10320-10325, Primary structure of Human Plasma Fibronectin.
Grijalva, Mario Javier, Ph.D., 1997, Immunological characterization of the antigen released in vitro byTrypanosma cruziinfected cells and determination of the risk of transfusion-associated transmission of Chagas disease in Ecudor. vol. 58/09-B of Dissertation Abstracts International, p. 4598, Ohio University, 141 pages, Abstract only.
Truyens, Carine et al, Experimental Parasitology, vol. 80, pp. 499-506, 1995, High Circulating levels of Fibronectin and antibodies against its RGD adhesin site during MouseTrypanosoma cruziinfection: relation to survival.
dos Santos, Paula V.A. e tal, Microbes and Infection, vol. 3, pp. 971-981, 2001, Prevalence of CD8+ alpha/Beta T cells inTrypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62Llow LFA-1highVLA-4High activation phenotype and expression of IFN-gamma inducible adhesion and chemoattractant molecules.
Noisin, EL et al, Infection and Immunity, vol. 57(4), p. 1030-1034, Apr. 1989, Fibronectin increasesTrypanosoma cruziAmastigote binding to and uptake by Murine Macrophages and Human monocytes.
Chiller, TM et al, Am. J. Trop. Med. Hyg. vol. 43(6), pp. 650-656, Igg antibody reactivity withTrypanosoma crugziandLeishmaniaantigens in sera of patients with Chagas disease and Leishmaniasis.
Mendes, Rodolfo P. et al, Journal of Clinical Microbiology, vol. 35(7), Jul. 1997, pp. 1829-1834, Serological Diagnosis of Chagas' Diease: a Potential Confimatory Assay using perserved protein antigens ofTrypaosoma cruzi.
Ferreira, Marcelo S e tal, Clinical Infectous Diseases, vol. 25(6), Dec. 1997, pp. 1397-1400, Reactivation of Chagas Disease in Patients with AIDS: Report of three new cases and Review of the Literature.
Ndao, M. et al, Journal of clinical microbiology, Apr. 2010, pp. 1139-1149, vol. 48, No. four, Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.
Cano, R. et al. “Levels of Apolipoproteins and Cholesterol of Low and High Density Lipoproteins in Asymptomatic Chagas Disease.”Medicina(Buenos Aires), 45(3):269-272 (1985).
dos Santos, P. V. A. et al. “Prevalence of CD84+αβ T cells inTrypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62LLowLFA-1HighVLA-4Highactivation phenotype and expression of IFN-γ-inducible adhesion and chemoattractant molecules.”Microbes and Infection, vol. 3, pp. 971-984 (2001).
Marino, A.P.M.P. at al. “Trypanosoma cruziinfection: a continuous invader-host cell cross talk with participation of extracellular matrix and adhesion and chemoattractant molecules.”Braz J Med Biol Res, 36(8):1121-1133 (2003).
Scharfstein, J. et al. “Induction of the Acute-Phase Protein Serum Amyloid P in Experimental Chagas' Disease.”Infection and Immunity, 35(1):46-51 (Jan. 1982).
Araújo-Jorge et al., “Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy”,J Infect Dis. Dec. 15, 2002;186(12):1823-8.
Avila et al., “Antibodies to Laminin in American Cutaneous Leishmaniasis,”Infect Immun. Jan. 1984; 43(1): 402-406.
Cotta-De-Almeida et al., “Trypanosoma cruziinfection modulates intrathymic contents of extracellular matrix ligands and receptors and alters thymocyte migration,”Eur J Immunol.Sep. 2003;33(9):2439-48.
Magalhaes,-Santos et al., “Fibrogenesis and collagen resorption in the heart and skeletal muscle ofCalomys callosusexperimentally infected withTrypanosoma cruzi: immunohistochemical identification of extracellular matrix components,”Mem Inst Oswaldo Cruz. Jul. 2002;97(5):703-10.
Pestel et al., “Polyclonal cell activity of a repeat peptide derived from the sequence of an 85-kilodalton surface protein ofTrypanosoma cruzitrypomastigotes,” Infect Immun. Feb. 1992; 60(2): 715-719.
Truyens et al., “High circulating levels of fibronectin and antibodies against its RGD adhesion site during mouseTrypanosoma cruziinfection: relation to survival,” May 1995;80(3):499-506.
European Supplementary Search Report, European Application No. 04813321.9, Jan. 28, 2009, 3 pages.
Ouaissi, A. et al., “Fibronectin Cleavage Fragments Provide a Growth Factor-Like Activity for the Differentiation ofTrypanosoma cruziTrypomastigotes to Amastigotes,” European Journal of Cell Biology, 1992, pp. 68-79, vol. 59, No. 1.
Poon, T.C.W. et al., “Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes,” Clinical Chemistry, American Association for Clinical Chemistry, May 1, 2003, pp. 752-760, vol. 49, No. 5.
Thulasiraman, V. et al., “Detection and Identification of Virulence Factors inYersinia pestisUsing SELDI Proteinchip® System,” Biotechniques, Informa Life Sciences Publishing, Feb. 1, 2001, pp. 428-432, vol. 30, No. 2.
European Patent Office Communication, European Patent Application No. EP 04813321.9, Aug. 24, 2010, six pages.
Rivarola, H.W. et al., “Trypanosoma cruziTrypanothione Reductase Inhibitors: Phenothiazines and Related Compounds Modify Experimental Chagas Disease Evolution,”Current Drug Targets—Cardiovascular&Haematological Disorders, 2002, vol. 2, No. 1, pp. 43-52.
Vartio, T. et al., “Monoclonal Antibody Against theN-terminal End of Human Plasma Fibronectin,”Biochem. J., 1983, vol. 215, pp. 147-151.
European Examination Report, European Application No. 04813321.9, Apr. 27, 2009, 7 pages.
Caffrey Rebecca
Li Hongshan
Ndao Momar
Perichon Regis
Podust Vladimir
Dowell & Dowell , P.C.
McGill University
Navarro Albert
Portner Ginny
LandOfFree
Serum biomarkers for Chagas disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serum biomarkers for Chagas disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serum biomarkers for Chagas disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265461